ACAndrew Crombie

Andrew Crombie

*This is an algorithmically generated author record based on publicly available information.

Andrew Crombie has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The aquastatin biosynthetic gene cluster encodes a versatile polyketide synthase capable of synthesising heteromeric depsides with diverse alkyl side chains

    by Nicolau Sbaraini, Andrew Crombie, John A. Kalaitzis, Daniel Vuong, Joe Bracegirdle, Fraser Windsor, Ashli Lau, Rachel Chen, Yu Pei Tan, Alastair Lacey, et al.

    The aqu BGC from Austroacremonium gemini encodes a versatile polyketide synthase capable of synthesising heteromeric depsides with diverse alkyl side chains.


  • Open Access

    Discovery and heterologous biosynthesis of glycosylated polyketide luteodienoside A reveals unprecedented glucinol-mediated product offloading by a fungal carnitine O-acyltransferase domain

    by Amr A. Arishi, Zhuo Shang, Ernest Lacey, Andrew Crombie, Daniel Vuong, Hang Li, Joe Bracegirdle, Peter Turner, William Lewis, Gavin R. Flematti, et al.

    Luteodienoside A – a glycosylated polyketide produced by the Australian fungus Aspergillus luteorubrus is biosynthesised by a polyketide synthase with a carnitine O-acyltransferase domain capable of adding glucinol to the polyketide product.


  • Semisynthesis and biological evaluation of a focused library of unguinol derivatives as next-generation antibiotics

    by Mahmud T. Morshed, Hang T. Nguyen, Daniel Vuong, Andrew Crombie, Ernest Lacey, Abiodun D. Ogunniyi, Stephen W. Page, Darren J. Trott, Andrew M. Piggott

    In this study, we report the semisynthesis and in vitro biological evaluation of thirty-four derivatives of the fungal depsidone antibiotic, unguinol. Initially, the semisynthetic modifications were focused on the two free hydroxy groups (3-OH and 8-OH), the three free aromatic positions (C-2, C-4 and C-7), the butenyl side chain and the depsidone ester linkage. Fifteen first-generation unguinol analogues were synthesised and screened against a panel of bacteria, fungi and mammalian cells to formulate a basic structure activity relationship (SAR) for the unguinol pharmacophore. Based on the SAR studies, we synthesised a further nineteen second-generation analogues, specifically aimed at improving the antibacterial potency of the pharmacophore. In vitro antibacterial activity testing of these compounds revealed that 3-O-(2-fluorobenzyl)unguinol and 3-O-(2,4-difluorobenzyl)unguinol showed potent activity against both methicillin-susceptible and methicillin-resistant Staphylococcus aureus (MIC 0.25–1 μg mL−1) and are promising candidates for further development in vivo.


  • Expanding antibiotic chemical space around the nidulin pharmacophore

    by Mahmud T. Morshed, Daniel Vuong, Andrew Crombie, Alastair E. Lacey, Peter Karuso, Ernest Lacey, Andrew M. Piggott

    Reinvestigating antibiotic scaffolds that were identified during the Golden Age of antibiotic discovery, but have long since been “forgotten”, has proven to be an effective strategy for delivering next-generation antibiotics capable of combatting multidrug-resistant superbugs. In this study, we have revisited the trichloro-substituted depsidone, nidulin, as a selective and unexploited antibiotic lead produced by the fungus Aspergillus unguis. Manipulation of halide ion concentration proved to be a powerful tool for modulating secondary metabolite production and triggering quiescent pathways in A. unguis. Supplementation of the culture media with chloride resulted in a shift in co-metabolite profile to dichlorounguinols and nornidulin at the expense of the non-chlorinated parent, unguinol. Surprisingly, only marginal enhancement of nidulin was observed, suggesting O-methylation may be rate-limiting. Similarly, supplementation of the media with bromide led to the production of the corresponding bromo-analogues, but also resulted in a novel family of depsides, the unguidepsides. Unexpectedly, depletion of chloride from the media halted the biosynthesis of the non-chlorinated parent compound, unguinol, and redirected biosynthesis to a novel family of ring-opened analogues, the unguinolic acids. Supplementation of the media with a range of unnatural salicylic acids failed to yield the corresponding nidulin analogues, suggesting the compounds may be biosynthesised by a single polyketide synthase. In total, 12 new and 11 previously reported nidulin analogues were isolated, characterised and assayed for in vitro activity against a panel of bacteria, fungi and mammalian cells, providing a comprehensive structure–activity profile for the nidulin scaffold.